Imiquimod is Highly Effective for Extensive, Hyperproliferative Condyloma in Children

Pediatric Dermatology

Volumn 20, Issue 5, 2003, Pages 440-442

  Majewski, Slawomir ^a   Pniewski, Tomasz ^a   Malejczyk, Magdalena ^a   Jablonska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ANUS; ARTICLE; CASE REPORT; CHILD SEXUAL ABUSE; CLINICAL FEATURE; CONDYLOMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFLAMMATION; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; VERRUCA VULGARIS; WART VIRUS;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INFANT;

EID: 0142040677     PISSN: 07368046     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1470.2003.20516.x     Document Type: Article

References (14)

1. Obalek MD, Misiewicz J, Jablonska S, Favre M, Orth G. Childhood condyloma acuminatum: association with genital and cutaneous human papillomaviruses. Pediatr Dermatol 1993;10:101-106.
2. Tseng CJ, Liang CC, Soong YK, Pao CC. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol 1998;91:92-96.
3. Syrjanen S, Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000;11:259-274.
4. Puranen M, Yliskoski M, Saarikoski SV, Syrjanen K, Syrjanen S. Perinatal transmission of human papillomavirus from infected mothers to their new-born babies and persistence of the virus in childhood. Am J Obstet Gynecol 1997;176:1039-1045.
5. Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results of a prospective cohort study. Am J Obstet Gynecol 1998;178:365-373.
6. Suzuki H, Wang B, Amerio P, et al. Imiquimod, a novel topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 1998;110:566-571.
7. 2 cytonine production with the immune response modifiers R-848 and imiquimod. Cell Immunol 1999;191:10-17.
8. Tomai MA, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Vasilakos JP. Effects of the imidazoquinolines, imiquimod and S-28463 on Th1 and Th2 cytokine response in vitro. J Invest Dermatol 1998;110:651-656.
9. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Acta Derm-Venered (submitted).
10. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-235.
11. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551.
12. Grussendorf-Conen EI, Jacobs S. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr Dermatol 2002;19:263-266.
13. Schaen L, Mercurio MG. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream. Pediatr Dermatol 2001;18:450-452.
14. Moresi JM, Herbert CR, Cohen BA. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream. Pediatr Dermatol 2001;18:448-450.